Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 19/20 | 0.85 |
| ▸ | MERTK | Q12866 | 19/20 | 0.85 |
| ▸ | FLT3 | P36888 | 1/20 | 0.84 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18580239 | 0.95 | AXL (0.88) | AXLMERTKFLT3TYRO3 | |
| SCHEMBL18579589 | 0.92 | AXL (1.00) | AXLMERTKFLT3TYRO3 | |
| SCHEMBL18579608 | 0.92 | AXL (0.89) | AXLMERTKFLT3TYRO3 | |
| SCHEMBL18580191 | 0.91 | AXL (1.00) | AXLMERTKFLT3TYRO3 | |
| SCHEMBL18580171 | 0.91 | AXL (1.00) | AXLMERTKFLT3TYRO3 | |
| SCHEMBL18580534 | 0.91 | AXL (1.00) | AXLMERTKFLT3TYRO3 | |
| SCHEMBL18579498 | 0.91 | AXL (0.90) | AXLMERTKFLT3TYRO3 | |
| SCHEMBL18580074 | 0.90 | AXL (0.86) | AXLMERTKFLT3TYRO3 | |
| SCHEMBL18579545 | 0.90 | AXL (0.89) | AXLMERTKFLT3TYRO3 | |
| SCHEMBL18580077 | 0.90 | AXL (1.00) | AXLMERTKFLT3TYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | claimed |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-03-16 | — | — | US | disclosed |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-03-16 | — | — | US | disclosed |
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2019-04-25 | — | — | US | disclosed |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2019-04-25 | — | — | US | disclosed |
| US-10125118-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2018-11-13 | — | — | US | disclosed |
| EP-3344613-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | Dong-A Socio Holdings Co., Ltd. (KR) | 2018-07-11 | — | — | EP | disclosed |
| US-20170355690-A9 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-12-14 | — | — | US | disclosed |
| US-20170355690-A9 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-12-14 | — | — | US | disclosed |
| US-20170355690-A9 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-12-14 | — | — | US | disclosed |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO LTD (KR) | 2017-03-09 | — | — | US | disclosed |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO LTD (KR) | 2017-03-09 | — | — | US | disclosed |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO LTD (KR) | 2017-03-09 | — | — | US | disclosed |
| WO-2017039331-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017039331-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355690-A9 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | AXL 30/4885MERTK 1/4885FLT3 34/4885 |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | AXL 30/4885MERTK 1/4885FLT3 34/4885 |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | AXL 30/4885MERTK 1/4885FLT3 34/4885 |
| US-10125118-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | AXL 30/4885MERTK 1/4885FLT3 34/4885 |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | AXL 30/4885MERTK 1/4885FLT3 34/4885 |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | AXL 30/4885MERTK 1/4885FLT3 34/4885 |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | AXL 30/4885MERTK 1/4885FLT3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.